Open an account

Nexien Biopharma

NXEN · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About NXEN

Nexien BioPharma, Inc. engages in the development and commercialization of Food and Drug Administration-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions. The company is headquartered in Glendale, Colorado. The company went IPO on 2001-07-11. The firm is focused on developing and commercializing United States Food and Drug Administration (FDA)-compliant cannabinoid pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders and medical conditions. The firm is utilizing cannabinoids as the active pharmaceutical ingredients to develop synthetic pharmaceuticals in strict accordance with the U.S. FDA pre-clinical and clinical pathways. Its flagship research and development programs are focused on advancing formulations that have the potential to improve the treatment outcomes of certain convulsive disorders and neuromuscular disorders, which includes the treatment of myotonic dystrophy. The firm's wholly owned subsidiaries include Intiva BioPharma Inc., NexN Inc. (NexN) and NexDM Inc.

Employees
0
Headquarters
Glendale, Colorado
Listed
Jul 11, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
nexienbiopharma.com

NXEN key statistics

Market cap
7.08K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
20.16K
Volume
10
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0018
52 Week low
$0.0001

Nexien Biopharma (NXEN) at a glance

Nexien Biopharma (NXEN) last traded at $0.0001, with a market cap of 7.08K and a price-to-earnings ratio of 0.00.

Volume so far is 10 shares, below the average of 20.16K shares a day.

Over the past year Nexien Biopharma has ranged from $0.0001 to $0.0018, and now sits 0% of the way up that range.

Nexien Biopharma met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY98 it reported -$0.30 per share against an estimate of -$0.306.

NXEN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 7.7% on average.

  1. 1996-09-30: reported -$0.63 per share against an estimate of $0.00
  2. Q1 FY97: reported -$0.12 per share against an estimate of -$0.0306
  3. Q2 FY97: reported $0.66 per share against an estimate of $0.5814
  4. Q3 FY97: reported $0.57 per share against an estimate of $0.612
  5. 1997-09-30: reported -$1.41 per share against an estimate of -$0.765
  6. Q1 FY98: reported -$1.35 per share against an estimate of -$0.306
  7. Q2 FY98: reported -$1.71 per share against an estimate of $0.00
  8. Q3 FY98: reported -$0.30 per share against an estimate of -$0.306

Similar companies

Companies in the same industry as Nexien Biopharma

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.